模型引导精准给药减少儿童长春新碱诱导的周围神经病变:药动学与药效学建模及模拟分析
该研究基于35例儿童肿瘤患者数据,建立长春新碱药动学与药效学模型,发现AUC是与周围神经病变(VIPN)最相关的暴露指标,AUC 50 ng·h/mL对应5次给药期间平均VIPN概率40%。模拟显示模型引导精准给药(MIPD)较体表面积给药使≥2级VIPN发生率从62.1%降至53.9%,支持MIPD用于儿童长春新碱剂量决策与个体化。
要点
- 长春新碱AUC是与VIPN发生最相关的暴露指标,AUC 50 ng·h/mL对应5次给药期间平均VIPN概率40%。
- MIPD较体表面积给药使≥2级VIPN发生率从62.1%降至53.9%。
- MIPD组81.4%患者减量、33.4%患者增量,标准给药组86.4%减量且不允许增量。
核心结论
- 药动学与药效学分析支持使用MIPD指导临床剂量决策并降低VIPN发生率。
- 当前工作可用于支持儿童长春新碱剂量选择与个体化决策。
研究设计与样本
- 利用35例儿童患者数据量化长春新碱剂量、暴露与VIPN发生的关系。
- 在基线和后续每次给药(1-5次)时测量长春新碱暴露和VIPN(CTCAE)。
- 进行药动学和药效学分析评估暴露与VIPN的个体间和个体内变异。
- 开展计算机模拟试验展示MIPD在特定年龄、体重和CYP3A5基因型分布儿科亚群中的效用。
主要发现
- 二室模型线性药动学良好描述长春新碱暴露数据,清除率和分布参数通过异速增长与体重相关。
- 含马尔可夫元素的比例优势模型描述0级、1级和≥2级VIPN过量给药场合的发生率。
- 长春新碱AUC是与VIPN发生最显著的暴露指标,AUC 50 ng·h/mL估计与5次给药期间平均VIPN概率40%相关。
- MIPD较体表面积给药使≥2级VIPN发生率从62.1%降至53.9%。
- MIPD组81.4%患者减量(标准给药组86.4%),33.4%患者增量(标准给药不允许增量)。
关键数值与推荐
- VIPN按CTCAE分级评估。
- AUC 50 ng·h/mL对应5次给药期间平均VIPN概率40%。
- MIPD较体表面积给药使≥2级VIPN发生率从62.1%降至53.9%。
- MIPD组81.4%患者减量、33.4%患者增量;标准给药组86.4%患者减量且不允许增量。
临床怎么用
- 可基于TDM测量计算患者长春新碱暴露,应用MIPD个体化剂量以降低VIPN风险。
- 剂量决策时可参考AUC与VIPN概率的关系,AUC 50 ng·h/mL对应5次给药期间平均VIPN概率40%。
局限性
- 研究基于35例儿童患者数据,样本量有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Vincristine-induced peripheral neuropathy (VIPN) is a common adverse effect of vincristine, a drug often used in pediatric oncology. Previous studies demonstrated large inter- and intrapatient variability in vincristine pharmacokinetics (PK). Model-informed precision dosing (MIPD) can be applied to calculate patient exposure and individualize dosing using therapeutic drug monitoring (TDM) measurements. This study set out to investigate the PK/pharmacodynamic (PKPD) relationship of VIPN and determine the utility of MIPD to support clinical decisions regarding dose selection and individualization. METHODS: Data from 35 pediatric patients were utilized to quantify the relationship between vincristine dose, exposure and the development of VIPN. Measurements of vincristine exposure and VIPN (Common Terminology Criteria for Adverse Events [CTCAE]) were available at baseline and for each subsequent dosing occasions (1-5). A PK and PKPD analysis was performed to assess the inter- and intraindividual variability in vincristine exposure and VIPN over time. In silico trials were performed to portray the utility of vincristine MIPD in pediatric subpopulations with a certain age, weight and cytochrome P450 (CYP) 3A5 genotype distribution. RESULTS: A two-compartmental model with linear PK provided a good description of the vincristine exposure data. Clearance and distribution parameters were related to bodyweight through allometric scaling. A proportional odds model with Markovian elements described the incidence of Grades 0, 1 and ≥ 2 VIPN overdosing occasions. Vincristine area under the curve (AUC) was the most significant exposure metric related to the development of VIPN, where an AUC of 50 ng⋅h/mL was estimated to be related to an average VIPN probability of 40% over five dosing occasions. The incidence of Grade ≥ 2 VIPN reduced from 62.1 to 53.9% for MIPD-based dosing compared with body surface area (BSA)-based dosing in patients. Dose decreases occurred in 81.4% of patients with MIPD (vs. 86.4% for standard dosing) and dose increments were performed in 33.4% of patients (no dose increments allowed for standard dosing). CONCLUSIONS: The PK and PKPD analysis supports the use of MIPD to guide clinical dose decisions and reduce the incidence of VIPN. The current work can be used to support decisions with respect to dose selection and dose individualization in children receiving vincristine.
引用
- Centanni M, van de Velde ME, Uittenboogaard A, et al. Model-Informed Precision Dosing to Reduce Vincristine-Induced Peripheral Neuropathy in Pediatric Patients: A Pharmacokinetic and Pharmacodynamic Modeling and Simulation Analysis. Clin Pharmacokinet. 2023. PMID: 38141094. doi:10.1007/s40262-023-01336-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。